There are no investors involved in todays action. With 50 Million shares outstanding and 75 million shares traded by noon today this is nothing but a bot war.
Alt has a marketcap of around $210 Million so with these results plus the possible nash data next quarter I feel this is extremely cheap when looking at the marketplace it will be entering.
I'm guessing they'll partner because they are very small (50 employees) with a very low cash burn.
Time will tell.
Altimmune price target raised to $25 from $16 at JMP Securities
JMP Securities raised the firm's price target on Altimmune to $25 from $16 and keeps an Outperform rating on the shares. Following the Phase 2b MOMENTUM data, the firm is now including obesity as a separate program in its Altimmune valuation. The shares are up 50% today but this still undervalues pemvidutide's opportunity that JMP now models at over $5B in peak sales between obesity and nonalcoholic steatohepatitis, the analyst tells investors in a research note. The firm continues to recommend Altimmune shares, saying pemvidutide has a competitive profile.
Market Data 
Markets 
AI
